FIG 4.
Combination of CCR5 blockers to inhibit HIV-1BaL infection. (A) HIV-1 inhibition induced by the combination of CCL5 with MVC tested by an acute-infection assay as described in the legend of Fig. 2. (B) CCL5 combination with MVC tested by a cell fusion inhibition assay using purified human CD4+ T cells. (A and B) The dose-response curves of mixed inhibitors (mix) are referred to as CCL5 (P values < 0.0001). (C to D) R4.0 in combination with CCL5 (C) or in triple combination with CCL5 and MVC (D) was tested as described above for panel A. (C and D) The dose-response curves of mixed inhibitors (mix) are referred to as R4.0 (P values < 0.0001). Values are the means ± SD from two independent experiments performed in triplicate.